CFTR modulator

Vanzacaftor/tezacaftor/deutivacaftor (Alyftrek)

The same idea as Trikafta, rebuilt: two medicines set the CFTR door in place and one opens it, now in a single dose a day. Who can take it still depends on which CFTR typo you carry.

What this drug connects to

The genes involved

CFTR

Cystic Fibrosis →

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) works the same way as Trikafta: two medicines move the CFTR door into place, and deutivacaftor, a slightly modified ivacaftor, opens it. The difference you notice is that it is taken once a day. The US label, revised in 2026, covers people aged 6 and older with cystic fibrosis who have at least one CFTR variant that still makes some CFTR protein or that tests show responds to it, confirmed with an FDA-cleared CF genetic test if the variants are not known. It carries the same boxed warning about the liver. Whether to take it is decided with a specialist, and nothing here is a reason to start, stop or change a medicine.

ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor) US prescribing information, revised 03/2026 (Vertex Pharmaceuticals; DailyMed).

In the news

2026-04-01 · Vertex Pharmaceuticals (FDA label expansion covering any CFTR variant shown to still produce CFTR protein, not just a fixed list of named mutations)

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK and TRIKAFTA, Expanding Availability to ~95% of All People With CF in the United States

FDA expanded the approved-use labels for two CFTR modulators -- Alyftrek (ages 6+) and Trikafta, which contains ivacaftor (ages 2+) -- from a fixed list of named mutations to any CFTR variant shown, by clinical or lab data, to still let the gene make CFTR protein: 564 variants qualify for Alyftrek, 521 for Trikafta. About 800 more people with CF in the US are now eligible, bringing total eligibility to roughly 95% of the US CF population -- a real-world example of exactly the variant-by-variant pharmacogenomic matching this page profiles.

Variants MyGeneLog™ reports for these genes

These are the positions in your own file that carry the genes above. Not every gene in a guideline is one we report — where that is the case the gene appears above without a variant here, and the note says so.

Barrett's esophagus or Esophageal adenocarcinoma

CFTR · rs17451754

Free Cholesterol to Cholesteryl Esters in Small HDL ratio

CFTR · rs145380885

Triglycerides to Total Lipids in Small HDL percentage

CFTR · rs6977665

Cystic fibrosis (F508del)

CFTR · rs113993960

Cystic fibrosis (G551D, a gating variant)

CFTR · rs75527207

Infective connective tissue disorders (PheCode 712)

CFTR · rs548335381

Questions about Vanzacaftor/tezacaftor/deutivacaftor (Alyftrek)

What is Alyftrek?

Alyftrek is a newer cystic fibrosis medicine, approved in the US in 2024, that you take once a day. Like Trikafta, it combines three drugs, vanzacaftor, tezacaftor and deutivacaftor: two set the faulty CFTR door in place, and one opens it. Whether you can take it depends on which CFTR typo you carry.

How is Alyftrek different from Trikafta?

Three practical differences. You take it once a day instead of morning and evening. It is approved from age 6, not 2. And two of its ingredients are different: vanzacaftor replaces elexacaftor, and deutivacaftor is a slightly modified ivacaftor. The idea, fix the door and then open it, is the same.

Which CFTR variants qualify for Alyftrek?

The same rule as Trikafta, from age 6: at least one CFTR variant that still makes some CFTR protein, or that tests have shown responds to the medicine. If your variants are not known yet, the label asks for an FDA-cleared CF genetic test first.

Does Alyftrek carry a safety warning?

Yes, the same boxed warning as Trikafta, the FDA's strongest kind, because serious liver damage has been seen with a medicine that shares its ingredients. You have a liver blood test before starting, every month for the first 6 months, every 3 months for the next 12 months, and at least once a year after that. Whether to take it is decided with a cystic fibrosis specialist; nothing here is a reason to start, stop or change a medicine.

Quoting this page

Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.

Vanzacaftor/tezacaftor/deutivacaftor (Alyftrek). MyGeneLog™. https://www.mygenelog.com/drugs/vanzacaftor-tezacaftor-deutivacaftor

This page is educational and contains no dosing information. Where a clinical guideline covers one of these gene-drug pairs it is written for prescribers and works through validated algorithms alongside clinical monitoring. Nothing here is a reason to start, stop, or change a medication — that conversation belongs with the clinician or pharmacist managing your treatment.